ARCH THERAPEUTICS

Terrence W. Norchi, MD
Chief Executive Officer

Michael S. Abrams
Chief Financial Officer



Cautionary Statement Regarding Forward-Looking Statements



This presentation includes forward-looking statements. We make forward-looking statements, as defined by the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, and in some cases, you can identify these statements by forward-looking words such as "if," "shall," "may," "might," "will likely result," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "goal," "objective," "predict," "potential" or "continue," or the negative of these terms and other comparable terminology. These include statements regarding: our ability to leverage our technology platform in the development of our lead and potential pipeline product candidates; our ability to design and conduct development activities and studies and clinical trials for our lead and potential pipeline product candidates; the potential timing and results of any such clinical trials we may conduct; our ability to obtain regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes in order to market any planned products; our ability to achieve financial projections; and our ability to achieve milestones. The forward-looking statements in this presentation are based on management's current expectations, estimates, forecasts and projections about the Company and its business, all of which could prove to wrong. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for our current and future fiscal years could differ materially from the Company's current expectations. Factors that could cause the Company's results to differ materially from those expressed in forward-looking statements include, without limitation, the following risks: we have estimated that we will have sufficient cash to operate our business for the near future, and we may not be able to obtain sufficient financing and/or establish necessary relationships with third parties to continue to pursue our business plan; the stockholder dilution that may result from future capital raising efforts and the exercise or conversion, as applicable of Arch's outstanding options and warrants; anti-dilution protection afforded investors in prior financing transactions that may restrict or prohibit Arch's ability to raise capital on terms favorable to the Company and its current stockholders; any development activities or clinical trials we may conduct may not produce favorable results; regulatory agencies may require that we undertake additional or more costly studies or clinical trials than we presently anticipate; we may never gain regulatory approval for any of our product candidates; we may not be able to protect our intellectual property rights; the intellectual property of others and any asserted claims of infringement; general business and economic conditions may limit our ability to obtain necessary capital; the consequences of competitive factors in the industry in which we operate may restrict the success of any product candidate we are able to commercialize, and we may not be able to attract or retain key personnel. More detailed information about us and the risk factors that may affect the realization of any forward-looking statements is set forth in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K filed on December 11, 2020 and subsequent filings with the SEC. Such documents may be read free of charge on the SEC's internet site at http://www.sec.gov. You are cautioned not to place undue reliance on any forward-looking statements we make in this presentation given these risks and uncertainties, and all such statements are qualified in their entirety by this cautionary statement. All forward-looking statements speak only as of the date hereof, and we undertake no obligation to revise or update any forward-looking statement to reflect events or circumstances after the date hereof, except as otherwise required by law.

Key Messages

Commercialization phase in progress



ARCH THERAPEUTICS

Breakthrough patented platform technology with multiple applications

Regulatory marketing authorization for initial products in US and EU

Critical inflection point in commercialization effort as hospitals reopen

Superior outcomes and value proposition supported by ongoing data collection

Robust product development pipeline targeting multiple market opportunities

Unique investment opportunity with compelling valuation

Key Statistics

OTCQB: ARTH

Shares Outstanding (as of May 5, 2021)	~237 million
Shares / Options Held by Mgmt. (~10%)	~25 million
Stock Options (outstanding and available)	~25 million
Trading Volume (90-day average)	~460,000
Cash (as of March 31, 2021)	~$5.6M
Current Cash Burn/Qtr.	~$1.5M
Debt	~$1.8M

Breakthrough Platform Technology

Improving lives with self-assembly



Advancing the Science of Healing

wound care • surgery • trauma

AC5 Technology Platform is Distinctive

Properties drive product advantages

AC5 compositions are designed to provide greater utility to clinicians and enable better outcomes for patients in diverse situations

- Short peptides self-assemble into a Nanofiber Network in the presence of ions (salt)
  - Network interacts with the tissue extra-cellular matrix (ECM)
- Starts as a barrier that seals tissue
  - Responsible for any hemostatic, sealant, anti-microbial and anti-inflammatory properties
- Builds a scaffold that enables cell migration/proliferation and repair of damaged tissue
  - Utility throughout all phases of wound healing
- Nanofiber Network is self-healing
  - Dynamically self-repairs around migrating cells
- Absorbed in concert with natural healing process
  - Enables accelerated healing



AC5 Dermal Sciences Value Proposition

Potential impact throughout the wound healing cascade



ARCH THERAPEUTICS

AC5 Advanced Wound System

- For the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds
- US 510(k) marketing authorization received

AC5 Topical Hemostat

- For use locally as a dressing and to control mild to moderate bleeding, each during the management of injured skin and the micro-environment of an acute surgical wound
- EU CE mark marketing authorization received

AC5® ADVANCED WOUND SYSTEM

Inflammatory → Proliferative → Remodeling

Barrier | Scaffold

Barrier	Barrier	Scaffold	Scaffold
Forms physical-mechanical seal	Provides protection	Creates ECM-like structure	Aids epithelialization[3]
Conforms to wound	May mitigate contamination and modulate inflammation[1, 2]	Enables cell and tissue growth	May benefit healing time
Provides moist healing environment			Naturally resorbed

AC5 Multi-modal Therapy System

[1] Anti-inflammatory effect of a self-assembling peptide (AC5®) in the lipopolysaccharide induced inflammation model of eye injury. Ellis-Behnke et al, Poster Presentation, MHSRS 08/18
[2] Effects of a self-assembling peptide on second degree burn progression and healing in a porcine model. Davis et al, Poster Presentation, SAWC Spring 2020
[3] Effects of a self-assembling peptide on full-thickness wound healing in a porcine model. Gil et al, Poster Presentation, SAWC Spring 2020

Dermal Sciences: AC5 Advanced Wound System

Healing of a recalcitrant trophic ulcer with co-morbidities

Patient History

- Scleroderma, Raynaud's phenomenon, peripheral vascular disease
- Past right below-the-knee amputation from prior wound
- Ulcer on remaining ankle failed to heal despite 4 years of interventions: debridement, skin substitutes, nitro paste, etc.

Use & Outcomes

- AC5 applied weekly x 3 with surgical debridement
- Wound closed by day 19

2021 Symposium on Advanced Wound Care | Wound Healing Society

- Earned Highest Scoring Poster / Abstract in "Case Series/Study" category
- Judged by independent panel of wound management experts

Progression of Healing



SAWC WHS

Dermal Sciences: Large Wound Management Market

Wound care products represent small portion of overall market costs

Medicare spending estimates for all wounds: $28 - $96 billion[2]

- Surgical wounds ~$12-38B
- Diabetic foot ulcers ~$6-19B



Commercially Available Wound Dressings[1]

Wound Dressings	2018 Sales ($Million)	2020 Est. Sales ($Million)	2025 Est. Salezs ($Million)
Advanced*	$1,802	$2.045	$2,744
Traditional	$1,116	$1,144	$1,211

*Moist, antimicrobial, interactive dressings and non-adherent contact layer dressings

Advanced Wound Dressings	2018 Sales ($Million)	2020 Est. Sales ($Million)	2025 Est. Sales ($Million)	2018 Ave. Selling Price ($)
Low-cost Skin Substitutes	$93	$105	$133	$320
High-cost Skin Substitutes	$733	$866	$1,254	$1,537

[1] US Market Report for Wound and Tissue Management, 2018, iData Research

[2] Nussbaum S, et al, An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. Value Health. 2018;21(1):27–32

Dermal Sciences Go to Market Strategy

Strategically driving US market penetration

Build Small Internal Sales Team

- Hire National Sales Director (√ July 2021)
- Hire 2 Regional Sales Directors (√ May and June 2021)
- Retain & train independent sales force with national footprint (√ Initiated and ongoing)
- Leverage Key Opinion Leaders (KOLs) to drive awareness and adoption
- Increase face-to-face contact with clinicians and decision-makers
- Build momentum

Gain Gov't Channel Mindshare; Sync with Re-Opening Trend

- Penetrate VA system by targeting individual hospitals
  - 170 hospitals and more than 1000 outpatient clinics
  - Ideal patient population for our products and technologies
- Secure inclusion in centralized government purchasing platform
- Affirm pricing relative to alternatives given initial impressive results and feedback

Pursue Non-Gov't Channels

- Target select self-pay applications
- Identify institutional opportunities, including single pay healthcare systems
- Pursue appropriate reimbursement codes

Source: Arch Therapeutics, Inc., data on file.

Key Messages

Commercialization phase in progress



ARCH THERAPEUTICS

Breakthrough patented platform technology with multiple applications

Regulatory marketing authorization for initial products in US and EU

Critical inflection point in commercialization effort as hospitals reopen

Superior outcomes and value proposition supported by ongoing data collection

Robust product development pipeline targeting multiple market opportunities

Unique investment opportunity with compelling valuation

ARCH THERAPEUTICS



Contact Information

235 Walnut Street, Suite 6
Framingham, MA 01702 USA

Investor Relations

Tel: 1.855.340.ARTH (2784)
investors@archtherapeutics.com